Preview Mode Links will not work in preview mode


Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of personalized medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Jul 20, 2020

Steven M. Fruchtman, M.D., President and Chief Executive Officer, Onconova Therapeutics discusses Rigosertib, a drug that has the potential to downregulate the RAS pathway, the most commonly mutated gene in cancer. Rigosertib is a proprietary phase 3 small molecule, currently being evaluated in second-line treatment of patients with higher-risk myelodysplastic syndrome (MDS) and refractory higher-risk MDS patients. Also known as pre-leukemia, MDS is a cancer of the bone marrow stem cell and the mission of Onconova is to prolong the lives of those suffering from this disease.


#cancer #oncology #RAS #MDS #PreLeukemia #Leukemia $ONTX

Download the transcript here